Short answer
UNITED THERAPEUTICS Corp (UTHR) filed an 8-K current report with the SEC on March 2, 2026 reporting Item 7.01 (Regulation FD Disclosure). Ralinepag Phase 3 ADVANCE OUTCOMES trial in pulmonary arterial hypertension (PAH) reported positive results: a potential major commercial catalyst for UTHR.
UNITED THERAPEUTICS Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Ralinepag Phase 3 ADVANCE OUTCOMES trial in pulmonary arterial hypertension (PAH) reported positive results: a potential major commercial catalyst for UTHR
- PAH is UTHR's core franchise; a successful Phase 3 outcome positions ralinepag as a next-generation oral prostacyclin receptor agonist competing in a high-value market
- Management webcast scheduled 8:30 a.m. ET, March 2, 2026 with slides available at ir.unither.com; key event for investors to assess clinical and commercial implications
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other UNITED THERAPEUTICS Corp 8-K filings
Get the next UTHR 8-K as it lands
Follow UTHR for push alerts, or ask the research agent what this filing means.